NVS vs PLXP

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

PLx Pharma Inc.

PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey.